CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced senior appointments to its ...
The FDA has become the latest organization to validate the potential of Vor Biopharma’s approach to CRISPR-powered cell engineering, granting fast-track status to its lead asset shortly after Johnson ...
Vor Biopharma VOR, a clinical-stage company, announced dosing the first patient in its phase I/II study of VCAR33 ALLO for the treatment of relapsed/refractory acute myeloid leukemia (AML). VCAR33 ...
Johnson & Johnson has teamed up with Vor Biopharma to study one of its bispecific antibodies in combination with technology designed to improve tolerability. Vor, which was founded by Siddhartha ...
A Cambridge biotech company using CRISPR gene editing to develop therapies for blood cancers said that its experimental treatment for acute myeloid leukemia proved safe in the first recipient, who is ...
BOSTON--(BUSINESS WIRE)--Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, today announced a $42 ...
Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering. The company's pipeline ...
PureTech Health plc (LSE: PRTC) ("PureTech"), a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for dysfunctions of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results